

Global Clinical Trial Imaging Market Report and Forecast 2023-2031

Market Report | 2023-06-15 | 140 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Clinical Trial Imaging Market Report and Forecast 2023-2031

Global Clinical Trial Imaging Market Outlook

The global clinical trial imaging market attained a value of USD 1.3 billion in 2022, driven by increasing number of clinical trials and advancements in imaging technologies. The market is expected to grow at a CAGR of 8.05% during the forecast period of 2023-2031 to attain a value of USD 2.5 billion by 2031.

Clinical Trial Imaging: Introduction

Clinical trial imaging refers to the use of various imaging modalities, such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and ultrasound, in clinical trials to assess and monitor the effects of investigational drugs or therapies on patients. It involves the acquisition, analysis, and interpretation of images to evaluate treatment response, disease progression, and safety outcomes. Clinical trial imaging offers several uses and benefits in the context of drug development and clinical research.

The uses of clinical trial imaging include:

- ☐ **Treatment Response Assessment:** Imaging techniques are employed to evaluate the response of patients to investigational drugs or therapies. They help assess the reduction in tumor size, changes in tumour characteristics, or improvements in disease-related biomarkers, providing objective measures of treatment efficacy.
- ☐ **Disease Progression Monitoring:** Imaging plays a crucial role in tracking disease progression and understanding the natural course of the disease. By capturing images at multiple time points during a clinical trial, researchers can assess disease dynamics, identify disease-related changes, and make informed decisions regarding treatment modifications or patient management.
- ☐ **Safety Evaluation:** Clinical trial imaging allows for the detection and monitoring of potential adverse effects or toxicities associated with investigational drugs or therapies. It helps identify any treatment-related complications, such as organ toxicity, changes in tissue structure, or abnormal physiological functions, enabling early intervention and improved patient safety.
- ☐ **Patient Selection and Stratification:** Imaging can assist in patient selection and stratification for clinical trials. It helps identify

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

patients with specific disease characteristics or biomarkers that may predict treatment response, aiding in the design of more targeted and personalized clinical trials.

-□Pharmacokinetic Studies: Imaging techniques, such as PET or MRI, can be utilized to assess the pharmacokinetics of drugs, tracking their distribution, metabolism, and elimination in the body. This information helps optimize drug dosing, determine optimal treatment regimens, and guide drug development decisions.

The benefits of clinical trial imaging include:

-□Objective and Quantitative Measurements: Imaging provides objective and quantitative data, enabling standardized assessments of treatment response and disease progression. This reduces subjectivity and enhances the reliability and reproducibility of study outcomes.

-□Early Detection of Treatment Response: Clinical trial imaging allows for the early detection of treatment response or lack thereof. This facilitates prompt adjustments in treatment strategies, leading to improved patient outcomes and more efficient clinical trial design.

-□Improved Trial Efficiency: The use of imaging in clinical trials can enhance trial efficiency by providing timely and accurate assessments of treatment effects. This can result in shorter trial durations, reduced sample sizes, and improved cost-effectiveness.

-□Non-Invasive Monitoring: Imaging techniques offer non-invasive methods of monitoring disease progression and treatment response, reducing the need for invasive procedures or repeated biopsies. This enhances patient comfort and compliance during clinical trials.

-□Enhanced Decision-making: Clinical trial imaging provides valuable information for decision-making, enabling researchers and clinicians to make more informed choices regarding treatment efficacy, patient selection, and drug development strategies.

It is important to note that the appropriate selection of imaging modalities, standardized imaging protocols, and rigorous image analysis methodologies are crucial for ensuring the accuracy and reliability of imaging data in clinical trials. Adherence to regulatory guidelines and ethical considerations regarding patient safety and privacy is essential throughout the imaging process.

Clinical Trial Imaging Market Segmentations

The market can be categorised into products and services, application, modality, end user, and region.

Market Breakup by Products and Services

-□Services

-□Software

Market Breakup by Application

-□Trial Design Consulting Services

-□Read Analysis Services

-□Operational Imaging Services

-□Imaging Software

Market Breakup by Modality

-□Magnetic Resonance Imaging

-□Computed Tomography

-□Ultrasound

-□Positron Emission Tomography

-□X-Ray

-□Echocardiography

-□Other Modalities

Market Breakup by End User

-□Pharmaceutical and Biotechnology Companies

-□Medical Device Manufacturers

-□Academic and Government Research Institutes

Market Breakup by Region

-□North America

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

Clinical Trial Imaging Market Overview

The clinical trial imaging market has experienced substantial growth and is expected to continue expanding in the coming years. Several factors contribute to the positive market scenario.

One of the primary drivers of market growth is the increasing number of clinical trials conducted worldwide. The pharmaceutical and biotechnology industries are investing heavily in drug development, and imaging plays a critical role in assessing treatment response and monitoring the safety and efficacy of investigational drugs. The rising demand for imaging services in clinical trials drives the growth of the clinical trial imaging market.

Moreover, the advancements in imaging technologies have significantly contributed to market expansion. The development of high-resolution imaging modalities, such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and molecular imaging, has improved the quality and accuracy of imaging data obtained during clinical trials. These advanced imaging techniques enable researchers to visualize and quantify treatment effects, disease progression, and therapeutic response, leading to more precise and reliable study outcomes.

Furthermore, the growing emphasis on personalized medicine and targeted therapies has increased the utilization of imaging in clinical trials. Imaging techniques play a crucial role in patient selection and stratification, enabling researchers to identify individuals with specific disease characteristics or biomarkers that may predict treatment response. This facilitates the design of more targeted and efficient clinical trials, leading to improved treatment outcomes and patient care.

In conclusion, the clinical trial imaging market is expected to witness continued growth due to the increasing number of clinical trials, advancements in imaging technologies, the emphasis on personalized medicine, and the recognition of regulatory agencies. The integration of imaging in clinical trials enhances the efficiency, accuracy, and reliability of study outcomes, leading to better decision-making in drug development and improved patient care. Continued investment in research and development, technological innovations, and collaborations between imaging service providers, pharmaceutical companies, and contract research organizations (CROs) will shape the future of the clinical trial imaging market.

Key players in the global clinical trial imaging market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the clinical trial imaging market are as follows:

- Navitas Life Sciences
- BioTelemetry
- ICON PLC
- IXICO plc.
- Image Core Lab
- anagram 4 clinical trials
- Quotient Sciences
- WORLD CARE CLINICAL
- Paraxel International Corporation
- Median Technologies

*We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1	Preface
1.1	Objectives of the Study
1.2	Key Assumptions
1.3	Report Coverage - Key Segmentation and Scope
1.4	Research Methodology
2	Executive Summary
3	Global Clinical Trial Imaging Market Overview
3.1	Global Clinical Trial Imaging Market Historical Value (2016-2022)
3.2	Global Clinical Trial Imaging Market Forecast Value (2023-2031)
4	Global Clinical Trial Imaging Market Dynamics
4.1	Market Drivers and Constraints
4.2	SWOT Analysis
4.3	Porter's Five Forces Model
4.4	Key Demand Indicators
4.5	Key Price Indicators
4.6	Industry Events, Initiatives, and Trends
4.7	Value Chain Analysis
5	Global Clinical Trial Imaging Market Segmentation
5.1	Global Clinical Trial Imaging Market by Products and Services
5.1.1	Market Overview
5.1.2	Services
5.1.3	Software
5.2	Global Clinical Trial Imaging Market by Application
5.2.1	Market Overview
5.2.2	Trial Design Consulting Services
5.2.3	Read Analysis Services
5.2.4	Operational Imaging Services
5.2.5	Imaging Software
5.3	Global Clinical Trial Imaging Market by Modality
5.3.1	Market Overview
5.3.2	Magnetic Resonance Imaging
5.3.3	Computed Tomography
5.3.4	Ultrasound
5.3.5	Positron Emission Tomography
5.3.6	X-Ray
5.3.7	Echocardiography
5.3.8	Other Modalities
5.4	Global Clinical Trial Imaging Market by End User
5.4.1	Market Overview
5.4.2	Pharmaceutical and Biotechnology Companies
5.4.3	Medical Device Manufacturers
5.4.4	Academic and Government Research Institutes
5.5	Global Clinical Trial Imaging Market by Region
5.5.1	Market Overview
5.5.2	North America
5.5.3	Europe
5.5.4	Asia Pacific

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.5.5 Latin America
- 5.5.6 Middle East and Africa
- 6 North America Clinical Trial Imaging Market
 - 6.1 Market Share by Country
 - 6.2 United States of America
 - 6.3 Canada
- 7 Europe Clinical Trial Imaging Market
 - 7.1 Market Share by Country
 - 7.2 United Kingdom
 - 7.3 Germany
 - 7.4 France
 - 7.5 Italy
 - 7.6 Others
- 8 Asia Pacific Clinical Trial Imaging Market
 - 8.1 Market Share by Country
 - 8.2 China
 - 8.3 Japan
 - 8.4 India
 - 8.5 ASEAN
 - 8.6 Australia
 - 8.7 Others
- 9 Latin America Clinical Trial Imaging Market
 - 9.1 Market Share by Country
 - 9.2 Brazil
 - 9.3 Argentina
 - 9.4 Mexico
 - 9.5 Others
- 10 Middle East and Africa Clinical Trial Imaging Market
 - 10.1 Market Share by Country
 - 10.2 Saudi Arabia
 - 10.3 United Arab Emirates
 - 10.4 Nigeria
 - 10.5 South Africa
 - 10.6 Others
- 11 Regulatory Framework
 - 11.1 Regulatory Overview
 - 11.1.1 US FDA
 - 11.1.2 EU EMA
 - 11.1.3 INDIA CDSCO
 - 11.1.4 JAPAN PMDA
 - 11.1.5 Others
- 12 Patent Analysis
 - 12.1 Analysis by Type of Patent
 - 12.2 Analysis by Publication year
 - 12.3 Analysis by Issuing Authority
 - 12.4 Analysis by Patent Age
 - 12.5 Analysis by CPC Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.6□Analysis by Patent Valuation
- 12.7□Analysis by Key Players
- 13□Grants Analysis
- 13.1□Analysis by year
- 13.2□Analysis by Amount Awarded
- 13.3□Analysis by Issuing Authority
- 13.4□Analysis by Grant Application
- 13.5□Analysis by Funding Institute
- 13.6□Analysis by NIH Departments
- 13.7□Analysis by Recipient Organization
- 14□Clinical Trials Analysis
- 14.1□ Analysis by Trial Registration Year
- 14.2□Analysis by Trial Status
- 14.3□Analysis by Trial Phase
- 14.4□Analysis by Therapeutic Area
- 14.5□Analysis by Geography
- 15□Funding and Investment Analysis
- 15.1□Analysis by Funding Instances
- 15.2□Analysis by Type of Funding
- 15.3□Analysis by Funding Amount
- 15.4□Analysis by Leading Players
- 15.5□Analysis by Leading Investors
- 15.6□Analysis by Geography
- 16□Partnership and Collaborations Analysis
- 16.1□Analysis by Partnership Instances
- 16.2□Analysis by Type of Partnership
- 16.3□Analysis by Leading Players
- 16.4□Analysis by Geography
- 17□Supplier Landscape
- 17.1□Navitas Life Sciences
- 17.1.1□Financial Analysis
- 17.1.2□Product Portfolio
- 17.1.3□Demographic Reach and Achievements
- 17.1.4□Mergers and Acquisitions
- 17.1.5□Certifications
- 17.2□BioTelemetry
- 17.2.1□Financial Analysis
- 17.2.2□Product Portfolio
- 17.2.3□Demographic Reach and Achievements
- 17.2.4□Mergers and Acquisitions
- 17.2.5□Certifications
- 17.3□ICON PLC
- 17.3.1□Financial Analysis
- 17.3.2□Product Portfolio
- 17.3.3□Demographic Reach and Achievements
- 17.3.4□Mergers and Acquisitions
- 17.3.5□Certifications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.4 IXICO plc.
 - 17.4.1 Financial Analysis
 - 17.4.2 Product Portfolio
 - 17.4.3 Demographic Reach and Achievements
 - 17.4.4 Mergers and Acquisitions
 - 17.4.5 Certifications
- 17.5 Image Core Lab
 - 17.5.1 Financial Analysis
 - 17.5.2 Product Portfolio
 - 17.5.3 Demographic Reach and Achievements
 - 17.5.4 Mergers and Acquisitions
 - 17.5.5 Certifications
- 17.6 anagram 4 clinical trials
 - 17.6.1 Financial Analysis
 - 17.6.2 Product Portfolio
 - 17.6.3 Demographic Reach and Achievements
 - 17.6.4 Mergers and Acquisitions
 - 17.6.5 Certifications
- 17.7 Quotient Sciences
 - 17.7.1 Financial Analysis
 - 17.7.2 Product Portfolio
 - 17.7.3 Demographic Reach and Achievements
 - 17.7.4 Mergers and Acquisitions
 - 17.7.5 Certifications
- 17.8 WORLD CARE CLINICAL
 - 17.8.1 Financial Analysis
 - 17.8.2 Product Portfolio
 - 17.8.3 Demographic Reach and Achievements
 - 17.8.4 Mergers and Acquisitions
 - 17.8.5 Certifications
- 17.9 Paraxel International Corporation
 - 17.9.1 Financial Analysis
 - 17.9.2 Product Portfolio
 - 17.9.3 Demographic Reach and Achievements
 - 17.9.4 Mergers and Acquisitions
 - 17.9.5 Certifications
- 17.10 Median Technologies
 - 17.10.1 Financial Analysis
 - 17.10.2 Product Portfolio
 - 17.10.3 Demographic Reach and Achievements
 - 17.10.4 Mergers and Acquisitions
 - 17.10.5 Certifications
- 18 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 19 Company Competitiveness Analysis (Additional Insight)
- 19.1 Very Small Companies
- 19.2 Small Companies

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

19.3□Mid-Sized Companies

19.4□Large Companies

19.5□Very Large Companies

20□Payment Methods (Additional Insight)

20.1□Government Funded

20.2□Private Insurance

20.3□Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Clinical Trial Imaging Market Report and Forecast 2023-2031

Market Report | 2023-06-15 | 140 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-05"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com